# US 8,278,458 B2 · Desferrithiocin polyether analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,458 B2
- Document ID: US8278458B2
- Status: Granted
- Kind: B2
- Application number: 11/973,001
- Filed: 2007-10-04
- Published: 2008-09-04
- Granted: 2012-10-02
- Earliest claimed: 2005-04-04
- Assignees: University of Florida Research Foundation, Inc.; University of Florida; The United States of America as represented by the National Institutes of Health (NIH); The United States of America as represented by the Department of Health and Human Services
- Inventors: Raymond J. Bergeron, Jr.
- Web page: https://patentgrep.com/patent/US8278458B2

## CPC

- C07D 277/12: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 31/426: 1,3-Thiazoles
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 39/04: Chelating agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 277/10: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07B 2200/07: Optical isomers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.

## Claims

### Claim 1

A compound represented by Structural Formula (I):
wherein:
R1 is —H or an acyl group;
R2 is —[(CH2)n—O]x—[(CH2)n—O]y—R′;
R3, R4 and R5 are each —H;
R6 and R7 are each —H;
R8 is —H or an alkyl group;
R9 is —OR12 or —N(OH)R13;
R10 is —H or an alkyl group;
R11 is —H, an alkyl group or an acyl group;
R12 is —H or an alkyl group;
R13 is an alkyl group;
R14 is an alkyl group;
R′ is an alkyl group;
m is an integer from 1 to 8;
each n is independently an integer from 1 to 8;
x is an integer from 1 to 8;
y is an integer from 0 to 8;
Z is —C(O)R14, or
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R9 is —OR12; R8 is —H or —CH3; and R3, R4, R5, R6, and R7 are each —H.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R2 is —[(CH2)n—O]x—R′; n is 1 to 4, and x is 1 to 4.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is represented by a structural formula selected from one of Structural Formulas (IV)-(IX):
or a salt of any of the foregoing.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the compound is represented by structural Formula VI:
or a salt thereof.

### Claim 6

A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I):
wherein:
R1 is —H or an acyl group;
R2 is —[(CH2)n—O]x—[(CH2)n—O]y—R′;
R3, R4 and R5 are each —H;
R6 and R7 are each —H;
R8 is —H or an alkyl group;
R9 is —OR12 or —N(OH)R13;
R10 is —H or an alkyl group;
R12 is —H or an alkyl group;
R13 is an alkyl group;
R14 is an alkyl group;
R′ is an alkyl group;
m is an integer from 1 to 8;
each n is independently an integer from 1 to 8;
x is an integer from 1 to 8;
y is an integer from 0 to 8;
Z is —C(O)R14, or
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein R9 is —OR12; R8 is —H or —CH3; and R3, R4, R5, R6, and R7 are each —H.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein R2 is —[(CH2)n—O]x—R′; n is 1 to 4; and x is 1 to 4.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is represented by a structural formula selected from one of Structural Formulas (IV)-(IX):
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the compound is represented by structural Formula VI:
or a pharmaceutically acceptable salt thereof.

### Claim 11

A method of treating trivalent metal overload in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I):
wherein:
R1 is —H or an acyl group;
R2 is —[(CH2)n—O]x—[(CH2)n—O]y—R′;
R3, R4 and R5 are each —H;
R6 and R7 are each —H;
R8 is —H or an alkyl group;
R9 is —OR12 or —N(OH)R13;
R10 is —H or an alkyl group;
R12 is —H or an alkyl group;
R13 is an alkyl group;
R14 is an alkyl group;
R′ is an alkyl group;
m is an integer from 1 to 8;
each n is independently an integer from 1 to 8;
x is an integer from 1 to 8;
y is an integer from 0 to 8;
Z is —C(O)R14, or
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein R9 is —OR12; R9 is —H or —CH3; and R3, R4, R5, R6, and R7 are each —H.

### Claim 13 (depends on 12)

The method of claim 12, wherein R2 is —[(CH2)n—O]x—R′; n is 1 to 4; and x is 1 to 4.

### Claim 14 (depends on 11)

The method of claim 11, wherein the compound is represented by a structural formula selected from one of Structural Formulas (IV)-(IX):
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound is represented by structural Formula VI:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 11)

The method of claim 11, wherein the trivalent metal overload is associated with deposition of the trivalent metal in the tissues of the subject, wherein the trivalent metal is iron or aluminum.

### Claim 17 (depends on 11)

The method of claim 11, wherein the trivalent metal overload is iron overload.

### Claim 18 (depends on 17)

The method of claim 17, wherein the trivalent metal overload is associated with hemochromatosis.
